NCT04165564|Active Not Recruiting
Loading search results
Sponsor study identifier
observational
85
1 country
19
Study Start
August 24, 2020
Actual (reported)Primary Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
DECAMP 1 PLUS aims to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules (8-25 mm). Molecular biomarkers for lung cancer diagnosis measured in minimally invasive and non-invasive biospecimens may be able to distinguish between malignant or benign indeterminate pulmonary nodules in high-risk smokers. Ultimately, this study aims to validate molecular as well as clinical and imaging biomarkers of lung cancer in individuals with indeterminate lung nodules.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 14, 2019
Actual (reported)November 18, 2019
Actual (reported)August 24, 2020
Actual (reported)December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Incidence of lung cancer
The number of new cases of lung cancer that developed divided by the population at risk.
3 years
Participants in this group will be 55-77 years old and currently smoke or were former smokers with 30 pack-years or more (and quit less than 15 years ago)
Participants in this group will be \> 45 years old and currently smoke or were former smokers with 10 pack-years or more (and quit less than 15 years ago)
Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
Patients are identified for inclusion in the study based on the observation of a lung nodule on screening or incidentally found by routine chest CT scans, between 0.8-2.5 cm diameter or observation of a mixed density nodule in which the solid portion is 0.6-2.5 cm diameter. These patients are managed according to institutional standard of care. This may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
University of Alabama, Birmingham
Birmingham, Alabama, 35233, United States
University of California Los Angeles
Los Angeles, California, 90095, United States
VA Greater LA Healthcare System
Los Angeles, California, 90095, United States
Naval Medical Center San Diego
San Diego, California, 92134, United States
University of Iowa
Iowa City, Iowa, 52242, United States
Walter Reed Army Medical Center
Bethesda, Maryland, 20889, United States
VA Boston Healthcare System
Boston, Massachusetts, 02110, United States
Blood, Nasal brushing, Buccal scraping, Stool, Bronchial Biopsy, Bronchial brushing, Lung tissue
Ehab Billatos, MD
Boston University
Denise Aberle, MD
University of California, Los Angeles
George Washko, MD
Brigham and Women's Hospital
85 participants (actual enrollment reported by the registry).
First Submitted
November 14, 2019
First Posted
November 18, 2019
Study Start
August 24, 2020
Actual (reported)Safety of a Sheath Cryoprobe Bronchoscopic Transbronchial Biopsy Technique
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
University of Michigan
Ann Arbor, Michigan, 48109, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
Cleveland Clinic
Cleveland, Ohio, 44195, United States
American College of Radiology [Administrative Site]
Philadelphia, Pennsylvania, 19103, United States
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, 19104, United States
Temple University
Philadelphia, Pennsylvania, 19140, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
Brown University [Administrative Site]
Providence, Rhode Island, 02912, United States
VA Tennessee Valley Healthcare System
Nashville, Tennessee, 37232, United States
MD Anderson Cancer Center [Administrative Site]
Houston, Texas, 77030, United States
Naval Medical Center Portsmouth
Portsmouth, Virginia, 23708, United States
West Virginia University
Morgantown, West Virginia, 26505, United States
Primary Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
April 1, 2026
Record last verified: 2026-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: